Home » Investor Relations

Lessons Learned: Prudent Management of Corporate Cash
0
Much has been written recently about the amount of cash companies are accumulating through their operations. In an August 2011 report, the Wall Street Journal noted that “non-financial companies in the Standard & Poor’s 500-stock index were holding...

Continue Reading »

VIDEO: Recap of Growth at AdvantEdge Healthcare Solutions, Bridgevine and MediaMath
0
Earlier this quarter at Safeguard Scientifics’ Investor Day, we provided further transparency into three of our technology partner companies, which have also experienced tremendous growth: MediaMath, AdvantEdge Healthcare Solutions, and Bridgevine. With...

Continue Reading »

VIDEO: The Next Big Thing in Digital Marketing and Advertising
0
Digital marketing is experiencing explosive growth, and both partner companies Bridgevine and MediaMath have taken advantage of this fast-growing industry. With the accelerating growth of mobile and social media, digital ad integration is one of the industry’s...

Continue Reading »

A Focus on Life Sciences

A Focus on Life Sciences

Posted by James A. Datin on November 23, 2011
0
Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that we believe will have success with applications they submit to the FDA. In addition,...

Continue Reading »

The Power of emPower!

The Power of emPower!

Posted by James A. Datin on November 21, 2011
0
PixelOptics’ emPower! eyewear is the world’s first and only electronic focusing eyeglasses—focusing faster than the blink of an eye. The technology is embedded inside the lenses and powered by tiny microelectronics hidden inside the frames, providing...

Continue Reading »

Opportunity in the Migraine Market for NuPathe
1
Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that are administered orally are less effective. Enter Zelrix, or NP101, which...

Continue Reading »